NASDAQ: COAGHemab Therapeutics Holdings Inc Stock
$34.00
Updated May 1, 2026
COAG Price
$34.00
Fair Value Price
N/A
Market Cap
N/A
52 Week Low
$27.00
52 Week High
$36.56
P/E
-0.5x
P/B
N/A
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$63.91M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-0.06
Operating Cash Flow
-$61M
Beta
N/A
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COAG Overview
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine COAG's potential to beat the market
- COAG doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important COAG news, forecast changes, insider trades & much more!
COAG News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how COAG scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COAG is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
COAG is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
COAG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more COAG due diligence checks available for Premium users.
Valuation
COAG price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.5x
Industry
29.05x
Market
18.83x
COAG's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
COAG's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$194.8M
Liabilities
$11.3M
Debt to equity
-0.06
COAG's short-term assets ($192.55M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COAG's short-term assets ($192.55M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COAG's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
COAG's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
COAG's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
Hemab Therapeutics Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.